Ankylosing Spondylitis Market by Drug Type (Nonsteroidal Anti-Inflammatory Drugs, TNF blockers, Immunosuppressive Drugs, Anti-Inflammatory Drugs, Steroids, JAK Inhibitors, Others (IL-17 Inhibitors); by Application (Juveniles, Adults); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026

Report ID :AMI-123 | Category : Therapeutic Area | Published Date :August, 2018 | Pages : 397 | Format :PDF
Buy Now!

Industry Trends

Ankylosing Spondylitis (AS) is a common chronic inflammatory rheumatic disease, which are seen in young adults, often in their late teens or early twenties. It can cause pain in lower back and neck. Over the time, AS can cause spine to become curved and rigid and affecting the shape of spine. Normally AS causes pain in spine but in some cases AS can cause swelling and pain in heels, chest, hips and shoulders. Early diagnosis is crucial in ankylosing spondylitis as spinal deformity can be minimized with the help of proper treatment.

Management of ankylosing spondylitis can be done with pharmacological and nonpharmacological treatments. Pharmacological treatments are limited but however researchers are working on innovations in biological drugs and improvements of the treatment in this field. These treatments involve preservation of physical function, control of inflammation and symptoms and stoppage of progressive structural damage and disabilities. In pharmacological treatments, non-steroidal anti-inflammatory drugs (NSAIDs) can help to reduce the symptoms and signs of axial movements with spondyloarthropathies. In many studies it has been observed that, NSAIDs provide great and rapid relief to inflammatory back pain. However, with this treatment, several rebound symptoms such as stiffness, swelling and joint pain can be observed after few days. Nonpharmacological treatments for ankylosing spondylitis involves regular exercise and patient training. It has been observed that these treatments are helpful in enhancement of spinal mobility parameters however they have not affected disease activity.

The ankylosing spondylitis market, in terms of revenue, was valued at US$ 5.34 Bn in 2017 and is expected to reach US$ 6.84 Bn by 2022.

Global Ankylosing Spondylitis Market, By Application, 2017 & 2022 (USD Billion)

Global Ankylosing Spondylitis Market

There is no cure for AS, but have several approved treatments to manage the symptoms, such as anti-inflammatory drugs, over-the-counter pain relievers, prescription medicines, as well as exercise program. Many research institutes are working on various therapy and diagnosis of ankylosing spondylitis. Radiographic studies are also helpful in the detection, diagnosis and monitoring of AS patients. Also, computed tomography can be used in some selected situations such as bone formations at various sites, sclerotic changes and erosions.

Poor prognosis for cure of ankylosing spondylitis can critically impact the ankylosing spondylitis market. As per NIAMS, AS generally occurs at young age often before 30s. The symptoms start with stiffness and pain which develops slowly over the week or months. Correct diagnosis and treatment can help to recover the symptoms which can slow down the development of disease.

Non-steroidal anti-inflammatory drugs (NSAIDs) can help to reduce the symptoms and signs of axial movements with spondyloarthropathies. In many studies it has been observed that, NSAIDs provide great and rapid relief in inflammatory back pain. There are some rebound symptoms such as stiffness, swelling and joint pain that can be observed after few days.

Ankylosing Spondylitis Market, by Region

Asia Pacific region represents a lot of opportunities for future growth in the market. The organizations and institutes in this region are investing heavily in R&D as there are not any approved treatments available for this disease. For instance, Novartis Pharmaceuticals in Japan is currently carrying clinical trial on patients for clinical efficacy and safety of secukinumab subcutaneous injections for the treatment of ankylosing spondylitis. The study was started in April 2016 and expected to complete in November 2018.

Competitive Market Share

The ankylosing spondylitis market report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions(M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.

Key participants of global ankylosing spondylitis market are AbbVie Inc, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Aventis, CELGENE Corporation, Celltrion Healthcare Co., Ltd., Eisai Co., Ltd., Galapagos NV, Protalix Ltd., Regeneron Pharmaceuticals, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, UCB S.A., and Xian Janssen Pharmaceutical Ltd amongst others.

 Ankylosing Spondylitis Industry Background

Global Ankylosing Spondylitis Market

Global Ankylosing Spondylitis Market

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    Ankylosing Spondylitis Market Snapshot

3.    Executive Summary: Ankylosing Spondylitis Market

4.    Qualitative Analysis: Ankylosing Spondylitis Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in Market

5.    Global Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

5.2.1.   Nonsteroidal Anti-Inflammatory Drugs

5.2.1.1.    Definition

5.2.1.2.    Market Penetration

5.2.1.3.    Market Revenue Expected to Increase by 2026

5.2.1.4.    Compound Annual Growth Rate (CAGR)

5.2.2.   TNF blockers

5.2.2.1.    Definition

5.2.2.2.    Market Penetration

5.2.2.3.    Market Revenue Expected to Increase by 2026

5.2.2.4.    Compound Annual Growth Rate (CAGR)

5.2.3.   Immunosuppressive Drugs

5.2.3.1.    Definition

5.2.3.2.    Market Penetration

5.2.3.3.    Market Revenue Expected to Increase by 2026

5.2.3.4.    Compound Annual Growth Rate (CAGR)

5.2.4.   Anti-Inflammatory Drugs

5.2.4.1.    Definition

5.2.4.2.    Market Penetration

5.2.4.3.    Market Revenue Expected to Increase by 2026

5.2.4.4.    Compound Annual Growth Rate (CAGR)

5.2.5.   Steroids

5.2.5.1.    Definition

5.2.5.2.    Market Penetration

5.2.5.3.    Market Revenue Expected to Increase by 2026

5.2.5.4.    Compound Annual Growth Rate (CAGR)

5.2.6.   JAK Inhibitors

5.2.6.1.    Definition

5.2.6.2.    Market Penetration

5.2.6.3.    Market Revenue Expected to Increase by 2026

5.2.6.4.    Compound Annual Growth Rate (CAGR)

5.2.7.   Others (IL-17 Inhibitors)

5.2.7.1.    Definition

5.2.7.2.    Market Penetration

5.2.7.3.    Market Revenue Expected to Increase by 2026

5.2.7.4.    Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1.   By Drug Type

6.    Global Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

6.2.1.   Juveniles

6.2.1.1.    Definition

6.2.1.2.    Market Penetration

6.2.1.3.    Market Revenue Expected to Increase by 2026

6.2.1.4.    Compound Annual Growth Rate (CAGR)

6.2.2.   Adults

6.2.2.1.    Definition

6.2.2.2.    Market Penetration

6.2.2.3.    Market Revenue Expected to Increase by 2026

6.2.2.4.    Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Application

7.    North America Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   North America Market Revenue (US$ Mn)

7.2.   North America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

7.2.1.   Nonsteroidal Anti-Inflammatory Drugs

7.2.2.   TNF blockers

7.2.3.   Immunosuppressive Drugs

7.2.4.   Anti-Inflammatory Drugs

7.2.5.   Steroids

7.2.6.   JAK Inhibitors

7.2.7.   Others (IL-17 Inhibitors)

7.3.   North America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

7.3.1.   Juveniles

7.3.2.   Adults

7.4.   North America Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1.    U.S. Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

7.4.1.1.1.    Nonsteroidal Anti-Inflammatory Drugs

7.4.1.1.2.    TNF blockers

7.4.1.1.3.    Immunosuppressive Drugs

7.4.1.1.4.    Anti-Inflammatory Drugs

7.4.1.1.5.    Steroids

7.4.1.1.6.    JAK Inhibitors

7.4.1.1.7.    Others (IL-17 Inhibitors)

7.4.1.2.    U.S. Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

7.4.1.2.1.    Juveniles

7.4.1.2.2.    Adults

7.4.2.   Rest of North America

7.4.2.1.    Rest of North America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

7.4.2.1.1.    Nonsteroidal Anti-Inflammatory Drugs

7.4.2.1.2.    TNF blockers

7.4.2.1.3.    Immunosuppressive Drugs

7.4.2.1.4.    Anti-Inflammatory Drugs

7.4.2.1.5.    Steroids

7.4.2.1.6.    JAK Inhibitors

7.4.2.1.7.    Others (IL-17 Inhibitors)

7.4.2.2.    Rest of North America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

7.4.2.2.1.    Juveniles

7.4.2.2.2.    Adults

7.5.   Key Segment for Channeling Investments

7.5.1.   By Country

7.5.2.   By Drug Type

7.5.3.   By Application

8.    Europe Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Europe Market Revenue (US$ Mn)

8.2.   Europe Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.2.1.   Nonsteroidal Anti-Inflammatory Drugs

8.2.2.   TNF blockers

8.2.3.   Immunosuppressive Drugs

8.2.4.   Anti-Inflammatory Drugs

8.2.5.   Steroids

8.2.6.   JAK Inhibitors

8.2.7.   Others (IL-17 Inhibitors)

8.3.   Europe Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.3.1.   Juveniles

8.3.2.   Adults

8.4.   Europe Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.    France Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.4.1.1.1.    Nonsteroidal Anti-Inflammatory Drugs

8.4.1.1.2.    TNF blockers

8.4.1.1.3.    Immunosuppressive Drugs

8.4.1.1.4.    Anti-Inflammatory Drugs

8.4.1.1.5.    Steroids

8.4.1.1.6.    JAK Inhibitors

8.4.1.1.7.    Others (IL-17 Inhibitors)

8.4.1.2.    France Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.4.1.2.1.    Juveniles

8.4.1.2.2.    Adults

8.4.2.   The UK

8.4.2.1.    The UK Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.4.2.1.1.    Nonsteroidal Anti-Inflammatory Drugs

8.4.2.1.2.    TNF blockers

8.4.2.1.3.    Immunosuppressive Drugs

8.4.2.1.4.    Anti-Inflammatory Drugs

8.4.2.1.5.    Steroids

8.4.2.1.6.    JAK Inhibitors

8.4.2.1.7.    Others (IL-17 Inhibitors)

8.4.2.2.    The UK Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.4.2.2.1.    Juveniles

8.4.2.2.2.    Adults

8.4.3.   Spain

8.4.3.1.    Spain Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.4.3.1.1.    Nonsteroidal Anti-Inflammatory Drugs

8.4.3.1.2.    TNF blockers

8.4.3.1.3.    Immunosuppressive Drugs

8.4.3.1.4.    Anti-Inflammatory Drugs

8.4.3.1.5.    Steroids

8.4.3.1.6.    JAK Inhibitors

8.4.3.1.7.    Others (IL-17 Inhibitors)

8.4.3.2.    Spain Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.4.3.2.1.    Juveniles

8.4.3.2.2.    Adults

8.4.4.   Germany

8.4.4.1.    Germany Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.4.4.1.1.    Nonsteroidal Anti-Inflammatory Drugs

8.4.4.1.2.    TNF blockers

8.4.4.1.3.    Immunosuppressive Drugs

8.4.4.1.4.    Anti-Inflammatory Drugs

8.4.4.1.5.    Steroids

8.4.4.1.6.    JAK Inhibitors

8.4.4.1.7.    Others (IL-17 Inhibitors)

8.4.4.2.    Germany Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.4.4.2.1.    Juveniles

8.4.4.2.2.    Adults

8.4.5.   Italy

8.4.5.1.    Italy Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.4.5.1.1.    Nonsteroidal Anti-Inflammatory Drugs

8.4.5.1.2.    TNF blockers

8.4.5.1.3.    Immunosuppressive Drugs

8.4.5.1.4.    Anti-Inflammatory Drugs

8.4.5.1.5.    Steroids

8.4.5.1.6.    JAK Inhibitors

8.4.5.1.7.    Others (IL-17 Inhibitors)

8.4.5.2.    Italy Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.4.5.2.1.    Juveniles

8.4.5.2.2.    Adults

8.4.6.   Rest of Europe

8.4.6.1.    Rest of Europe Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.4.6.1.1.    Nonsteroidal Anti-Inflammatory Drugs

8.4.6.1.2.    TNF blockers

8.4.6.1.3.    Immunosuppressive Drugs

8.4.6.1.4.    Anti-Inflammatory Drugs

8.4.6.1.5.    Steroids

8.4.6.1.6.    JAK Inhibitors

8.4.6.1.7.    Others (IL-17 Inhibitors)

8.4.6.2.    Rest of Europe Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

8.4.6.2.1.    Juveniles

8.4.6.2.2.    Adults

8.5.   Key Segment for Channeling Investments

8.5.1.   By Country

8.5.2.   By Drug Type

8.5.3.   By Application

9.    Asia Pacific Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Asia Pacific Market Revenue (US$ Mn)

9.2.   Asia Pacific Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.2.1.   Nonsteroidal Anti-Inflammatory Drugs

9.2.2.   TNF blockers

9.2.3.   Immunosuppressive Drugs

9.2.4.   Anti-Inflammatory Drugs

9.2.5.   Steroids

9.2.6.   JAK Inhibitors

9.2.7.   Others (IL-17 Inhibitors)

9.3.   Asia Pacific Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

9.3.1.   Juveniles

9.3.2.   Adults

9.4.   Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1.    China Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.4.1.1.1.    Nonsteroidal Anti-Inflammatory Drugs

9.4.1.1.2.    TNF blockers

9.4.1.1.3.    Immunosuppressive Drugs

9.4.1.1.4.    Anti-Inflammatory Drugs

9.4.1.1.5.    Steroids

9.4.1.1.6.    JAK Inhibitors

9.4.1.1.7.    Others (IL-17 Inhibitors)

9.4.1.2.    China Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

9.4.1.2.1.    Juveniles

9.4.1.2.2.    Adults

9.4.2.   Japan

9.4.2.1.    Japan Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.4.2.1.1.    Nonsteroidal Anti-Inflammatory Drugs

9.4.2.1.2.    TNF blockers

9.4.2.1.3.    Immunosuppressive Drugs

9.4.2.1.4.    Anti-Inflammatory Drugs

9.4.2.1.5.    Steroids

9.4.2.1.6.    JAK Inhibitors

9.4.2.1.7.    Others (IL-17 Inhibitors)

9.4.2.2.    Japan Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

9.4.2.2.1.    Juveniles

9.4.2.2.2.    Adults

9.4.3.   India

9.4.3.1.    India Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.4.3.1.1.    Nonsteroidal Anti-Inflammatory Drugs

9.4.3.1.2.    TNF blockers

9.4.3.1.3.    Immunosuppressive Drugs

9.4.3.1.4.    Anti-Inflammatory Drugs

9.4.3.1.5.    Steroids

9.4.3.1.6.    JAK Inhibitors

9.4.3.1.7.    Others (IL-17 Inhibitors)

9.4.3.2.    India Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

9.4.3.2.1.    Juveniles

9.4.3.2.2.    Adults

9.4.4.   Southeast Asia

9.4.4.1.    Southeast Asia Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.4.4.1.1.    Nonsteroidal Anti-Inflammatory Drugs

9.4.4.1.2.    TNF blockers

9.4.4.1.3.    Immunosuppressive Drugs

9.4.4.1.4.    Anti-Inflammatory Drugs

9.4.4.1.5.    Steroids

9.4.4.1.6.    JAK Inhibitors

9.4.4.1.7.    Others (IL-17 Inhibitors)

9.4.4.2.    Southeast Asia Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

9.4.4.2.1.    Juveniles

9.4.4.2.2.    Adults

9.4.5.   Rest of Asia Pacific

9.4.5.1.    Rest of Asia Pacific Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.4.5.1.1.    Nonsteroidal Anti-Inflammatory Drugs

9.4.5.1.2.    TNF blockers

9.4.5.1.3.    Immunosuppressive Drugs

9.4.5.1.4.    Anti-Inflammatory Drugs

9.4.5.1.5.    Steroids

9.4.5.1.6.    JAK Inhibitors

9.4.5.1.7.    Others (IL-17 Inhibitors)

9.4.5.2.    Rest of Asia Pacific Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

9.4.5.2.1.    Juveniles

9.4.5.2.2.    Adults

9.5.   Key Segment for Channeling Investments

9.5.1.   By Country

9.5.2.   By Drug Type

9.5.3.   By Application

10. Middle East and Africa Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Market Revenue (US$ Mn)

10.2. Middle East and Africa Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.2.1. Nonsteroidal Anti-Inflammatory Drugs

10.2.2. TNF blockers

10.2.3. Immunosuppressive Drugs

10.2.4. Anti-Inflammatory Drugs

10.2.5. Steroids

10.2.6. JAK Inhibitors

10.2.7. Others (IL-17 Inhibitors)

10.3. Middle East and Africa Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

10.3.1. Juveniles

10.3.2. Adults

10.4. Middle East and Africa Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1.  GCC Countries Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.4.1.1.1.  Nonsteroidal Anti-Inflammatory Drugs

10.4.1.1.2.  TNF blockers

10.4.1.1.3.  Immunosuppressive Drugs

10.4.1.1.4.  Anti-Inflammatory Drugs

10.4.1.1.5.  Steroids

10.4.1.1.6.  JAK Inhibitors

10.4.1.1.7.  Others (IL-17 Inhibitors)

10.4.1.2.  GCC Countries Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

10.4.1.2.1.  Juveniles

10.4.1.2.2.  Adults

10.4.2. Southern Africa

10.4.2.1.  Southern Africa Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.4.2.1.1.  Nonsteroidal Anti-Inflammatory Drugs

10.4.2.1.2.  TNF blockers

10.4.2.1.3.  Immunosuppressive Drugs

10.4.2.1.4.  Anti-Inflammatory Drugs

10.4.2.1.5.  Steroids

10.4.2.1.6.  JAK Inhibitors

10.4.2.1.7.  Others (IL-17 Inhibitors)

10.4.2.2.  Southern Africa Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

10.4.2.2.1.  Juveniles

10.4.2.2.2.  Adults

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.4.3.1.1.  Nonsteroidal Anti-Inflammatory Drugs

10.4.3.1.2.  TNF blockers

10.4.3.1.3.  Immunosuppressive Drugs

10.4.3.1.4.  Anti-Inflammatory Drugs

10.4.3.1.5.  Steroids

10.4.3.1.6.  JAK Inhibitors

10.4.3.1.7.  Others (IL-17 Inhibitors)

10.4.3.2.  Rest of MEA Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

10.4.3.2.1.  Juveniles

10.4.3.2.2.  Adults

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Drug Type

10.5.3. By Application

11. Latin America Ankylosing Spondylitis Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Market Revenue (US$ Mn)

11.2. Latin America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.2.1. Nonsteroidal Anti-Inflammatory Drugs

11.2.2. TNF blockers

11.2.3. Immunosuppressive Drugs

11.2.4. Anti-Inflammatory Drugs

11.2.5. Steroids

11.2.6. JAK Inhibitors

11.2.7. Others (IL-17 Inhibitors)

11.3. Latin America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Juveniles

11.3.2. Adults

11.4. Latin America Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1.  Brazil Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.4.1.1.1.  Nonsteroidal Anti-Inflammatory Drugs

11.4.1.1.2.  TNF blockers

11.4.1.1.3.  Immunosuppressive Drugs

11.4.1.1.4.  Anti-Inflammatory Drugs

11.4.1.1.5.  Steroids

11.4.1.1.6.  JAK Inhibitors

11.4.1.1.7.  Others (IL-17 Inhibitors)

11.4.1.2.  Brazil Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

11.4.1.2.1.  Juveniles

11.4.1.2.2.  Adults

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.4.2.1.1.  Nonsteroidal Anti-Inflammatory Drugs

11.4.2.1.2.  TNF blockers

11.4.2.1.3.  Immunosuppressive Drugs

11.4.2.1.4.  Anti-Inflammatory Drugs

11.4.2.1.5.  Steroids

11.4.2.1.6.  JAK Inhibitors

11.4.2.1.7.  Others (IL-17 Inhibitors)

11.4.2.2.  Rest of Latin America Ankylosing Spondylitis Market Revenue (US$ Mn) and Forecasts, By Application

11.4.2.2.1.  Juveniles

11.4.2.2.2.  Adults

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Drug Type

11.5.3. By Application

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. AbbVie Inc

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. Amgen Inc.

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Bristol-Myers Squibb Company

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

13.4. F. Hoffmann-La Roche Ltd.,

13.4.1. Company Details

13.4.2. Company Overview

13.4.3. Product Offerings

13.4.4. Key Developments

13.4.5. Financial Analysis

13.4.6. SWOT Analysis

13.4.7. Business Strategies

13.5. Merck & Co., Inc.,

13.5.1. Company Details

13.5.2. Company Overview

13.5.3. Product Offerings

13.5.4. Key Developments

13.5.5. Financial Analysis

13.5.6. SWOT Analysis

13.5.7. Business Strategies

13.6. Novartis AG

13.6.1. Company Details

13.6.2. Company Overview

13.6.3. Product Offerings

13.6.4. Key Developments

13.6.5. Financial Analysis

13.6.6. SWOT Analysis

13.6.7. Business Strategies

13.7. Pfizer Inc.

13.7.1. Company Details

13.7.2. Company Overview

13.7.3. Product Offerings

13.7.4. Key Developments

13.7.5. Financial Analysis

13.7.6. SWOT Analysis

13.7.7. Business Strategies

13.8. Sanofi Aventis

13.8.1. Company Details

13.8.2. Company Overview

13.8.3. Product Offerings

13.8.4. Key Developments

13.8.5. Financial Analysis

13.8.6. SWOT Analysis

13.8.7. Business Strategies

13.9. CELGENE Corporation

13.9.1. Company Details

13.9.2. Company Overview

13.9.3. Product Offerings

13.9.4. Key Developments

13.9.5. Financial Analysis

13.9.6. SWOT Analysis

13.9.7. Business Strategies

13.10. Celltrion Healthcare Co., Ltd.,

13.10.1.  Company Details

13.10.2.  Company Overview

13.10.3.  Product Offerings

13.10.4.  Key Developments

13.10.5.  Financial Analysis

13.10.6.  SWOT Analysis

13.10.7.  Business Strategies

13.11. Eisai Co., Ltd

13.11.1.  Company Details

13.11.2.  Company Overview

13.11.3.  Product Offerings

13.11.4.  Key Developments

13.11.5.  Financial Analysis

13.11.6.  SWOT Analysis

13.11.7.  Business Strategies

13.12. Galapagos NV

13.12.1.  Company Details

13.12.2.  Company Overview

13.12.3.  Product Offerings

13.12.4.  Key Developments

13.12.5.  Financial Analysis

13.12.6.  SWOT Analysis

13.12.7.  Business Strategies

13.13. Protalix Ltd.,

13.13.1.  Company Details

13.13.2.  Company Overview

13.13.3.  Product Offerings

13.13.4.  Key Developments

13.13.5.  Financial Analysis

13.13.6.  SWOT Analysis

13.13.7.  Business Strategies

13.14. Regeneron Pharmaceuticals, Inc.

13.14.1.  Company Details

13.14.2.  Company Overview

13.14.3.  Product Offerings

13.14.4.  Key Developments

13.14.5.  Financial Analysis

13.14.6.  SWOT Analysis

13.14.7.  Business Strategies

13.15. Shanghai Pharmaceuticals Holding Co., Ltd

13.15.1.  Company Details

13.15.2.  Company Overview

13.15.3.  Product Offerings

13.15.4.  Key Developments

13.15.5.  Financial Analysis

13.15.6.  SWOT Analysis

13.15.7.  Business Strategies

13.16. UCB S.A.

13.16.1.  Company Details

13.16.2.  Company Overview

13.16.3.  Product Offerings

13.16.4.  Key Developments

13.16.5.  Financial Analysis

13.16.6.  SWOT Analysis

13.16.7.  Business Strategies

13.17. Xian Janssen Pharmaceutical Ltd

13.17.1.  Company Details

13.17.2.  Company Overview

13.17.3.  Product Offerings

13.17.4.  Key Developments

13.17.5.  Financial Analysis

13.17.6.  SWOT Analysis

13.17.7.  Business Strategies

 

 Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once